BRAF V600E
|
Pancreatic Cancer
|
BRAF V600E
|
Pancreatic Cancer
|
cobimetinib Sensitive: C4 – Case Studies
Cold Spring Harb Mol Case Stud - 6 days
|
cobimetinib Sensitive: C4 – Case Studies
Cold Spring Harb Mol Case Stud - 6 days
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
cetuximab + encorafenib Sensitive: A1 - Approval
FDA - 3 weeks
|
cetuximab + encorafenib Sensitive: A1 - Approval
FDA - 3 weeks
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval
|
cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
dabrafenib Sensitive: A1 - Approval
|
dabrafenib Sensitive: A1 - Approval
|
BRAF V600E
|
NSCLC
|
BRAF V600E
|
NSCLC
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
BRAF V600E
|
Thyroid Gland Anaplastic Carcinoma
|
BRAF V600E
|
Thyroid Gland Anaplastic Carcinoma
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
BRAF V600E
|
Thyroid Gland Anaplastic Carcinoma
|
BRAF V600E
|
Thyroid Gland Anaplastic Carcinoma
|
dabrafenib Sensitive: A1 - Approval
|
dabrafenib Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
vemurafenib + cobimetinib Sensitive: A1 - Approval
|
vemurafenib + cobimetinib Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
vemurafenib Sensitive: A1 - Approval
|
vemurafenib Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
trametinib Sensitive: A1 - Approval
|
trametinib Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
encorafenib + binimetinib Sensitive: A1 - Approval
|
encorafenib + binimetinib Sensitive: A1 - Approval
|
BRAF V600E
|
NSCLC
|
BRAF V600E
|
NSCLC
|
vemurafenib Sensitive: A2 - Guideline
|
vemurafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
GBM
|
BRAF V600E
|
GBM
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
vemurafenib Sensitive: A2 - Guideline
|
vemurafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Biliary Tract Cancer
|
BRAF V600E
|
Biliary Tract Cancer
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Glioma
|
BRAF V600E
|
Glioma
|
selumetinib Sensitive: A2 - Guideline
|
selumetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
cobimetinib Sensitive: A2 - Guideline
|
cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
vemurafenib Sensitive: A2 - Guideline
|
vemurafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
trametinib Sensitive: A2 - Guideline
|
trametinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
dabrafenib Sensitive: A2 - Guideline
|
dabrafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
cobimetinib Sensitive: A2 - Guideline
|
cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
trametinib Sensitive: A2 - Guideline
|
trametinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
dabrafenib Sensitive: A2 - Guideline
|
dabrafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
panitumumab + encorafenib Sensitive: A2 - Guideline
|
panitumumab + encorafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
trametinib + dabrafenib + panitumumab Sensitive: A2 - Guideline
|
trametinib + dabrafenib + panitumumab Sensitive: A2 - Guideline
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline
|
cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
encorafenib + binimetinib Sensitive: A2 - Guideline
|
encorafenib + binimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
dabrafenib Sensitive: A2 - Guideline
|
dabrafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
vemurafenib Sensitive: A2 - Guideline
|
vemurafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Biliary Tract Cancer
|
BRAF V600E
|
Biliary Tract Cancer
|
pembrolizumab + lenvatinib Sensitive: A2 - Guideline
|
pembrolizumab + lenvatinib Sensitive: A2 - Guideline
|
BRAF V600E
|
GBM
|
BRAF V600E
|
GBM
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
trifluridine/tipiracil Sensitive: B - Late Trials
|
trifluridine/tipiracil Sensitive: B - Late Trials
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
cetuximab Resistant: B - Late Trials
|
cetuximab Resistant: B - Late Trials
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
encorafenib Sensitive: B - Late Trials
|
encorafenib Sensitive: B - Late Trials
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
encorafenib Sensitive: B - Late Trials
|
encorafenib Sensitive: B - Late Trials
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
encorafenib + binimetinib Sensitive: B - Late Trials
|
encorafenib + binimetinib Sensitive: B - Late Trials
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
bevacizumab Resistant: B - Late Trials
|
bevacizumab Resistant: B - Late Trials
|
BRAF V600E
|
NSCLC
|
BRAF V600E
|
NSCLC
|
dabrafenib Sensitive: C1 - Off-label
|
dabrafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Neuroendocrine Tumor
|
BRAF V600E
|
Neuroendocrine Tumor
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Neurofibrosarcoma
|
BRAF V600E
|
Neurofibrosarcoma
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Ovarian Serous Adenocarcinoma
|
BRAF V600E
|
Ovarian Serous Adenocarcinoma
|
encorafenib + binimetinib Sensitive: C1 - Off-label
|
encorafenib + binimetinib Sensitive: C1 - Off-label
|
BRAF V600E
|
GBM
|
BRAF V600E
|
GBM
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Pancreatic Cancer
|
BRAF V600E
|
Pancreatic Cancer
|
encorafenib + binimetinib Sensitive: C1 - Off-label
|
encorafenib + binimetinib Sensitive: C1 - Off-label
|
BRAF V600E
|
Solid Tumor
|
BRAF V600E
|
Solid Tumor
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Cholangiocarcinoma
|
BRAF V600E
|
Cholangiocarcinoma
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
GBM
|
BRAF V600E
|
GBM
|
dabrafenib Sensitive: C1 - Off-label
|
dabrafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
LUAD
|
BRAF V600E
|
LUAD
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Multiple Myeloma
|
BRAF V600E
|
Multiple Myeloma
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Ovarian Cancer
|
BRAF V600E
|
Ovarian Cancer
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Ovarian Cancer
|
BRAF V600E
|
Ovarian Cancer
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Head and Neck Cancer
|
BRAF V600E
|
Head and Neck Cancer
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
dabrafenib Sensitive: C1 - Off-label
|
dabrafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
trametinib Sensitive: C1 - Off-label
|
trametinib Sensitive: C1 - Off-label
|
BRAF V600E
|
Thyroid Gland Carcinoma
|
BRAF V600E
|
Thyroid Gland Carcinoma
|
dabrafenib Sensitive: C1 - Off-label
|
dabrafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Thyroid Gland Carcinoma
|
BRAF V600E
|
Thyroid Gland Carcinoma
|
trametinib Sensitive: C1 - Off-label
|
trametinib Sensitive: C1 - Off-label
|
BRAF V600E
|
Thyroid Gland Papillary Carcinoma
|
BRAF V600E
|
Thyroid Gland Papillary Carcinoma
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Solid Tumor
|
BRAF V600E
|
Solid Tumor
|
encorafenib + binimetinib Sensitive: C1 - Off-label
|
encorafenib + binimetinib Sensitive: C1 - Off-label
|
BRAF V600E
|
Thyroid Gland Papillary Carcinoma
|
BRAF V600E
|
Thyroid Gland Papillary Carcinoma
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Thyroid Gland Anaplastic Carcinoma
|
BRAF V600E
|
Thyroid Gland Anaplastic Carcinoma
|
vemurafenib Resistant: C1 - Off-label
|
vemurafenib Resistant: C1 - Off-label
|
BRAF V600E
|
Thyroid Gland Carcinoma
|
BRAF V600E
|
Thyroid Gland Carcinoma
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Pancreatic Cancer
|
BRAF V600E
|
Pancreatic Cancer
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Ocular Melanoma
|
BRAF V600E
|
Ocular Melanoma
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
NSCLC
|
BRAF V600E
|
NSCLC
|
trametinib Sensitive: C1 - Off-label
|
trametinib Sensitive: C1 - Off-label
|
BRAF V600E
|
Gastric Cancer
|
BRAF V600E
|
Gastric Cancer
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Biliary Tract Cancer
|
BRAF V600E
|
Biliary Tract Cancer
|
trametinib Sensitive: C1 - Off-label
|
trametinib Sensitive: C1 - Off-label
|
BRAF V600E
|
Multiple Myeloma
|
BRAF V600E
|
Multiple Myeloma
|
vemurafenib + cobimetinib Sensitive: C1 - Off-label
|
vemurafenib + cobimetinib Sensitive: C1 - Off-label
|
BRAF V600E
|
Glioma
|
BRAF V600E
|
Glioma
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
NSCLC
|
BRAF V600E
|
NSCLC
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
selumetinib Sensitive: C2 – Inclusion Criteria
|
selumetinib Sensitive: C2 – Inclusion Criteria
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
pembrolizumab + trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria
|
pembrolizumab + trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
cetuximab + vemurafenib Sensitive: C2 – Inclusion Criteria
|
cetuximab + vemurafenib Sensitive: C2 – Inclusion Criteria
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
vemurafenib + panitumumab Sensitive: C2 – Inclusion Criteria
|
vemurafenib + panitumumab Sensitive: C2 – Inclusion Criteria
|
BRAF V600E
|
Hairy Cell Leukemia
|
BRAF V600E
|
Hairy Cell Leukemia
|
dabrafenib Sensitive: C2 – Inclusion Criteria
|
dabrafenib Sensitive: C2 – Inclusion Criteria
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
vemurafenib + atezolizumab + cobimetinib Sensitive: C2 – Inclusion Criteria
|
vemurafenib + atezolizumab + cobimetinib Sensitive: C2 – Inclusion Criteria
|
BRAF V600E
|
Solid Tumor
|
BRAF V600E
|
Solid Tumor
|
trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria
|
trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
trametinib + dabrafenib + PDR001 Sensitive: C2 – Inclusion Criteria
|
trametinib + dabrafenib + PDR001 Sensitive: C2 – Inclusion Criteria
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
cetuximab + vemurafenib Sensitive: C2 – Inclusion Criteria
|
cetuximab + vemurafenib Sensitive: C2 – Inclusion Criteria
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
ipilimumab Sensitive: C2 – Inclusion Criteria
|
ipilimumab Sensitive: C2 – Inclusion Criteria
|
BRAF V600E
|
Hairy Cell Leukemia
|
BRAF V600E
|
Hairy Cell Leukemia
|
vemurafenib Sensitive: C2 – Inclusion Criteria
|
vemurafenib Sensitive: C2 – Inclusion Criteria
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
